Global Liposomal-based Drug Supply, Demand and Key Producers, 2023-2029
The global Liposomal-based Drug market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
This report studies the global Liposomal-based Drug demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Liposomal-based Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Liposomal-based Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Liposomal-based Drug total market, 2018-2029, (USD Million)
Global Liposomal-based Drug total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Liposomal-based Drug total market, key domestic companies and share, (USD Million)
Global Liposomal-based Drug revenue by player and market share 2018-2023, (USD Million)
Global Liposomal-based Drug total market by Type, CAGR, 2018-2029, (USD Million)
Global Liposomal-based Drug total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Liposomal-based Drug market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Johnson & Johnson, Sun Pharmaceutical, CSPC, Kinyond, Teva, Fudan-Zhangjiang, Zydus Cadila, TTY Biopharma and Pacira, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Liposomal-based Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Liposomal-based Drug Market, By Region:
1. How big is the global Liposomal-based Drug market?
2. What is the demand of the global Liposomal-based Drug market?
3. What is the year over year growth of the global Liposomal-based Drug market?
4. What is the total value of the global Liposomal-based Drug market?
5. Who are the major players in the global Liposomal-based Drug market?
6. What are the growth factors driving the market demand?
Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
This report studies the global Liposomal-based Drug demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Liposomal-based Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Liposomal-based Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Liposomal-based Drug total market, 2018-2029, (USD Million)
Global Liposomal-based Drug total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Liposomal-based Drug total market, key domestic companies and share, (USD Million)
Global Liposomal-based Drug revenue by player and market share 2018-2023, (USD Million)
Global Liposomal-based Drug total market by Type, CAGR, 2018-2029, (USD Million)
Global Liposomal-based Drug total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Liposomal-based Drug market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Johnson & Johnson, Sun Pharmaceutical, CSPC, Kinyond, Teva, Fudan-Zhangjiang, Zydus Cadila, TTY Biopharma and Pacira, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Liposomal-based Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Liposomal-based Drug Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Liposomes Drugs
- Lipid Nanoparticle Drugs
- Hospital
- Retail Pharmacy
- Other
- Johnson & Johnson
- Sun Pharmaceutical
- CSPC
- Kinyond
- Teva
- Fudan-Zhangjiang
- Zydus Cadila
- TTY Biopharma
- Pacira
- Luye Pharma
- Leadiant Biosciences
- Ipsen
- Sayre Therapeutics
- Jazz
- Alnylam
- Bausch Health
- Acrotech Biopharma
- Takeda
- Chiesi Farmaceutici
- Gilead Sciences
1. How big is the global Liposomal-based Drug market?
2. What is the demand of the global Liposomal-based Drug market?
3. What is the year over year growth of the global Liposomal-based Drug market?
4. What is the total value of the global Liposomal-based Drug market?
5. Who are the major players in the global Liposomal-based Drug market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Liposomal-based Drug Introduction
1.2 World Liposomal-based Drug Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Liposomal-based Drug Total Market by Region (by Headquarter Location)
1.3.1 World Liposomal-based Drug Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Liposomal-based Drug Market Size (2018-2029)
1.3.3 China Liposomal-based Drug Market Size (2018-2029)
1.3.4 Europe Liposomal-based Drug Market Size (2018-2029)
1.3.5 Japan Liposomal-based Drug Market Size (2018-2029)
1.3.6 South Korea Liposomal-based Drug Market Size (2018-2029)
1.3.7 ASEAN Liposomal-based Drug Market Size (2018-2029)
1.3.8 India Liposomal-based Drug Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Liposomal-based Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Liposomal-based Drug Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Liposomal-based Drug Consumption Value (2018-2029)
2.2 World Liposomal-based Drug Consumption Value by Region
2.2.1 World Liposomal-based Drug Consumption Value by Region (2018-2023)
2.2.2 World Liposomal-based Drug Consumption Value Forecast by Region (2024-2029)
2.3 United States Liposomal-based Drug Consumption Value (2018-2029)
2.4 China Liposomal-based Drug Consumption Value (2018-2029)
2.5 Europe Liposomal-based Drug Consumption Value (2018-2029)
2.6 Japan Liposomal-based Drug Consumption Value (2018-2029)
2.7 South Korea Liposomal-based Drug Consumption Value (2018-2029)
2.8 ASEAN Liposomal-based Drug Consumption Value (2018-2029)
2.9 India Liposomal-based Drug Consumption Value (2018-2029)
3 WORLD LIPOSOMAL-BASED DRUG COMPANIES COMPETITIVE ANALYSIS
3.1 World Liposomal-based Drug Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Liposomal-based Drug Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Liposomal-based Drug in 2022
3.2.3 Global Concentration Ratios (CR8) for Liposomal-based Drug in 2022
3.3 Liposomal-based Drug Company Evaluation Quadrant
3.4 Liposomal-based Drug Market: Overall Company Footprint Analysis
3.4.1 Liposomal-based Drug Market: Region Footprint
3.4.2 Liposomal-based Drug Market: Company Product Type Footprint
3.4.3 Liposomal-based Drug Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Liposomal-based Drug Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Liposomal-based Drug Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Liposomal-based Drug Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Liposomal-based Drug Consumption Value Comparison
4.2.1 United States VS China: Liposomal-based Drug Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Liposomal-based Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Liposomal-based Drug Companies and Market Share, 2018-2023
4.3.1 United States Based Liposomal-based Drug Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Liposomal-based Drug Revenue, (2018-2023)
4.4 China Based Companies Liposomal-based Drug Revenue and Market Share, 2018-2023
4.4.1 China Based Liposomal-based Drug Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Liposomal-based Drug Revenue, (2018-2023)
4.5 Rest of World Based Liposomal-based Drug Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Liposomal-based Drug Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Liposomal-based Drug Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Liposomal-based Drug Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Liposomes Drugs
5.2.2 Lipid Nanoparticle Drugs
5.3 Market Segment by Type
5.3.1 World Liposomal-based Drug Market Size by Type (2018-2023)
5.3.2 World Liposomal-based Drug Market Size by Type (2024-2029)
5.3.3 World Liposomal-based Drug Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Liposomal-based Drug Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Retail Pharmacy
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Liposomal-based Drug Market Size by Application (2018-2023)
6.3.2 World Liposomal-based Drug Market Size by Application (2024-2029)
6.3.3 World Liposomal-based Drug Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Johnson & Johnson
7.1.1 Johnson & Johnson Details
7.1.2 Johnson & Johnson Major Business
7.1.3 Johnson & Johnson Liposomal-based Drug Product and Services
7.1.4 Johnson & Johnson Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Johnson & Johnson Recent Developments/Updates
7.1.6 Johnson & Johnson Competitive Strengths & Weaknesses
7.2 Sun Pharmaceutical
7.2.1 Sun Pharmaceutical Details
7.2.2 Sun Pharmaceutical Major Business
7.2.3 Sun Pharmaceutical Liposomal-based Drug Product and Services
7.2.4 Sun Pharmaceutical Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Sun Pharmaceutical Recent Developments/Updates
7.2.6 Sun Pharmaceutical Competitive Strengths & Weaknesses
7.3 CSPC
7.3.1 CSPC Details
7.3.2 CSPC Major Business
7.3.3 CSPC Liposomal-based Drug Product and Services
7.3.4 CSPC Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 CSPC Recent Developments/Updates
7.3.6 CSPC Competitive Strengths & Weaknesses
7.4 Kinyond
7.4.1 Kinyond Details
7.4.2 Kinyond Major Business
7.4.3 Kinyond Liposomal-based Drug Product and Services
7.4.4 Kinyond Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Kinyond Recent Developments/Updates
7.4.6 Kinyond Competitive Strengths & Weaknesses
7.5 Teva
7.5.1 Teva Details
7.5.2 Teva Major Business
7.5.3 Teva Liposomal-based Drug Product and Services
7.5.4 Teva Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Teva Recent Developments/Updates
7.5.6 Teva Competitive Strengths & Weaknesses
7.6 Fudan-Zhangjiang
7.6.1 Fudan-Zhangjiang Details
7.6.2 Fudan-Zhangjiang Major Business
7.6.3 Fudan-Zhangjiang Liposomal-based Drug Product and Services
7.6.4 Fudan-Zhangjiang Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Fudan-Zhangjiang Recent Developments/Updates
7.6.6 Fudan-Zhangjiang Competitive Strengths & Weaknesses
7.7 Zydus Cadila
7.7.1 Zydus Cadila Details
7.7.2 Zydus Cadila Major Business
7.7.3 Zydus Cadila Liposomal-based Drug Product and Services
7.7.4 Zydus Cadila Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Zydus Cadila Recent Developments/Updates
7.7.6 Zydus Cadila Competitive Strengths & Weaknesses
7.8 TTY Biopharma
7.8.1 TTY Biopharma Details
7.8.2 TTY Biopharma Major Business
7.8.3 TTY Biopharma Liposomal-based Drug Product and Services
7.8.4 TTY Biopharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 TTY Biopharma Recent Developments/Updates
7.8.6 TTY Biopharma Competitive Strengths & Weaknesses
7.9 Pacira
7.9.1 Pacira Details
7.9.2 Pacira Major Business
7.9.3 Pacira Liposomal-based Drug Product and Services
7.9.4 Pacira Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Pacira Recent Developments/Updates
7.9.6 Pacira Competitive Strengths & Weaknesses
7.10 Luye Pharma
7.10.1 Luye Pharma Details
7.10.2 Luye Pharma Major Business
7.10.3 Luye Pharma Liposomal-based Drug Product and Services
7.10.4 Luye Pharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Luye Pharma Recent Developments/Updates
7.10.6 Luye Pharma Competitive Strengths & Weaknesses
7.11 Leadiant Biosciences
7.11.1 Leadiant Biosciences Details
7.11.2 Leadiant Biosciences Major Business
7.11.3 Leadiant Biosciences Liposomal-based Drug Product and Services
7.11.4 Leadiant Biosciences Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Leadiant Biosciences Recent Developments/Updates
7.11.6 Leadiant Biosciences Competitive Strengths & Weaknesses
7.12 Ipsen
7.12.1 Ipsen Details
7.12.2 Ipsen Major Business
7.12.3 Ipsen Liposomal-based Drug Product and Services
7.12.4 Ipsen Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Ipsen Recent Developments/Updates
7.12.6 Ipsen Competitive Strengths & Weaknesses
7.13 Sayre Therapeutics
7.13.1 Sayre Therapeutics Details
7.13.2 Sayre Therapeutics Major Business
7.13.3 Sayre Therapeutics Liposomal-based Drug Product and Services
7.13.4 Sayre Therapeutics Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Sayre Therapeutics Recent Developments/Updates
7.13.6 Sayre Therapeutics Competitive Strengths & Weaknesses
7.14 Jazz
7.14.1 Jazz Details
7.14.2 Jazz Major Business
7.14.3 Jazz Liposomal-based Drug Product and Services
7.14.4 Jazz Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Jazz Recent Developments/Updates
7.14.6 Jazz Competitive Strengths & Weaknesses
7.15 Alnylam
7.15.1 Alnylam Details
7.15.2 Alnylam Major Business
7.15.3 Alnylam Liposomal-based Drug Product and Services
7.15.4 Alnylam Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Alnylam Recent Developments/Updates
7.15.6 Alnylam Competitive Strengths & Weaknesses
7.16 Bausch Health
7.16.1 Bausch Health Details
7.16.2 Bausch Health Major Business
7.16.3 Bausch Health Liposomal-based Drug Product and Services
7.16.4 Bausch Health Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Bausch Health Recent Developments/Updates
7.16.6 Bausch Health Competitive Strengths & Weaknesses
7.17 Acrotech Biopharma
7.17.1 Acrotech Biopharma Details
7.17.2 Acrotech Biopharma Major Business
7.17.3 Acrotech Biopharma Liposomal-based Drug Product and Services
7.17.4 Acrotech Biopharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Acrotech Biopharma Recent Developments/Updates
7.17.6 Acrotech Biopharma Competitive Strengths & Weaknesses
7.18 Takeda
7.18.1 Takeda Details
7.18.2 Takeda Major Business
7.18.3 Takeda Liposomal-based Drug Product and Services
7.18.4 Takeda Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.18.5 Takeda Recent Developments/Updates
7.18.6 Takeda Competitive Strengths & Weaknesses
7.19 Chiesi Farmaceutici
7.19.1 Chiesi Farmaceutici Details
7.19.2 Chiesi Farmaceutici Major Business
7.19.3 Chiesi Farmaceutici Liposomal-based Drug Product and Services
7.19.4 Chiesi Farmaceutici Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.19.5 Chiesi Farmaceutici Recent Developments/Updates
7.19.6 Chiesi Farmaceutici Competitive Strengths & Weaknesses
7.20 Gilead Sciences
7.20.1 Gilead Sciences Details
7.20.2 Gilead Sciences Major Business
7.20.3 Gilead Sciences Liposomal-based Drug Product and Services
7.20.4 Gilead Sciences Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.20.5 Gilead Sciences Recent Developments/Updates
7.20.6 Gilead Sciences Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Liposomal-based Drug Industry Chain
8.2 Liposomal-based Drug Upstream Analysis
8.3 Liposomal-based Drug Midstream Analysis
8.4 Liposomal-based Drug Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Liposomal-based Drug Introduction
1.2 World Liposomal-based Drug Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Liposomal-based Drug Total Market by Region (by Headquarter Location)
1.3.1 World Liposomal-based Drug Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Liposomal-based Drug Market Size (2018-2029)
1.3.3 China Liposomal-based Drug Market Size (2018-2029)
1.3.4 Europe Liposomal-based Drug Market Size (2018-2029)
1.3.5 Japan Liposomal-based Drug Market Size (2018-2029)
1.3.6 South Korea Liposomal-based Drug Market Size (2018-2029)
1.3.7 ASEAN Liposomal-based Drug Market Size (2018-2029)
1.3.8 India Liposomal-based Drug Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Liposomal-based Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Liposomal-based Drug Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Liposomal-based Drug Consumption Value (2018-2029)
2.2 World Liposomal-based Drug Consumption Value by Region
2.2.1 World Liposomal-based Drug Consumption Value by Region (2018-2023)
2.2.2 World Liposomal-based Drug Consumption Value Forecast by Region (2024-2029)
2.3 United States Liposomal-based Drug Consumption Value (2018-2029)
2.4 China Liposomal-based Drug Consumption Value (2018-2029)
2.5 Europe Liposomal-based Drug Consumption Value (2018-2029)
2.6 Japan Liposomal-based Drug Consumption Value (2018-2029)
2.7 South Korea Liposomal-based Drug Consumption Value (2018-2029)
2.8 ASEAN Liposomal-based Drug Consumption Value (2018-2029)
2.9 India Liposomal-based Drug Consumption Value (2018-2029)
3 WORLD LIPOSOMAL-BASED DRUG COMPANIES COMPETITIVE ANALYSIS
3.1 World Liposomal-based Drug Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Liposomal-based Drug Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Liposomal-based Drug in 2022
3.2.3 Global Concentration Ratios (CR8) for Liposomal-based Drug in 2022
3.3 Liposomal-based Drug Company Evaluation Quadrant
3.4 Liposomal-based Drug Market: Overall Company Footprint Analysis
3.4.1 Liposomal-based Drug Market: Region Footprint
3.4.2 Liposomal-based Drug Market: Company Product Type Footprint
3.4.3 Liposomal-based Drug Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Liposomal-based Drug Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Liposomal-based Drug Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Liposomal-based Drug Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Liposomal-based Drug Consumption Value Comparison
4.2.1 United States VS China: Liposomal-based Drug Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Liposomal-based Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Liposomal-based Drug Companies and Market Share, 2018-2023
4.3.1 United States Based Liposomal-based Drug Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Liposomal-based Drug Revenue, (2018-2023)
4.4 China Based Companies Liposomal-based Drug Revenue and Market Share, 2018-2023
4.4.1 China Based Liposomal-based Drug Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Liposomal-based Drug Revenue, (2018-2023)
4.5 Rest of World Based Liposomal-based Drug Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Liposomal-based Drug Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Liposomal-based Drug Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Liposomal-based Drug Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Liposomes Drugs
5.2.2 Lipid Nanoparticle Drugs
5.3 Market Segment by Type
5.3.1 World Liposomal-based Drug Market Size by Type (2018-2023)
5.3.2 World Liposomal-based Drug Market Size by Type (2024-2029)
5.3.3 World Liposomal-based Drug Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Liposomal-based Drug Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Retail Pharmacy
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Liposomal-based Drug Market Size by Application (2018-2023)
6.3.2 World Liposomal-based Drug Market Size by Application (2024-2029)
6.3.3 World Liposomal-based Drug Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Johnson & Johnson
7.1.1 Johnson & Johnson Details
7.1.2 Johnson & Johnson Major Business
7.1.3 Johnson & Johnson Liposomal-based Drug Product and Services
7.1.4 Johnson & Johnson Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Johnson & Johnson Recent Developments/Updates
7.1.6 Johnson & Johnson Competitive Strengths & Weaknesses
7.2 Sun Pharmaceutical
7.2.1 Sun Pharmaceutical Details
7.2.2 Sun Pharmaceutical Major Business
7.2.3 Sun Pharmaceutical Liposomal-based Drug Product and Services
7.2.4 Sun Pharmaceutical Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Sun Pharmaceutical Recent Developments/Updates
7.2.6 Sun Pharmaceutical Competitive Strengths & Weaknesses
7.3 CSPC
7.3.1 CSPC Details
7.3.2 CSPC Major Business
7.3.3 CSPC Liposomal-based Drug Product and Services
7.3.4 CSPC Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 CSPC Recent Developments/Updates
7.3.6 CSPC Competitive Strengths & Weaknesses
7.4 Kinyond
7.4.1 Kinyond Details
7.4.2 Kinyond Major Business
7.4.3 Kinyond Liposomal-based Drug Product and Services
7.4.4 Kinyond Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Kinyond Recent Developments/Updates
7.4.6 Kinyond Competitive Strengths & Weaknesses
7.5 Teva
7.5.1 Teva Details
7.5.2 Teva Major Business
7.5.3 Teva Liposomal-based Drug Product and Services
7.5.4 Teva Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Teva Recent Developments/Updates
7.5.6 Teva Competitive Strengths & Weaknesses
7.6 Fudan-Zhangjiang
7.6.1 Fudan-Zhangjiang Details
7.6.2 Fudan-Zhangjiang Major Business
7.6.3 Fudan-Zhangjiang Liposomal-based Drug Product and Services
7.6.4 Fudan-Zhangjiang Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Fudan-Zhangjiang Recent Developments/Updates
7.6.6 Fudan-Zhangjiang Competitive Strengths & Weaknesses
7.7 Zydus Cadila
7.7.1 Zydus Cadila Details
7.7.2 Zydus Cadila Major Business
7.7.3 Zydus Cadila Liposomal-based Drug Product and Services
7.7.4 Zydus Cadila Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Zydus Cadila Recent Developments/Updates
7.7.6 Zydus Cadila Competitive Strengths & Weaknesses
7.8 TTY Biopharma
7.8.1 TTY Biopharma Details
7.8.2 TTY Biopharma Major Business
7.8.3 TTY Biopharma Liposomal-based Drug Product and Services
7.8.4 TTY Biopharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 TTY Biopharma Recent Developments/Updates
7.8.6 TTY Biopharma Competitive Strengths & Weaknesses
7.9 Pacira
7.9.1 Pacira Details
7.9.2 Pacira Major Business
7.9.3 Pacira Liposomal-based Drug Product and Services
7.9.4 Pacira Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Pacira Recent Developments/Updates
7.9.6 Pacira Competitive Strengths & Weaknesses
7.10 Luye Pharma
7.10.1 Luye Pharma Details
7.10.2 Luye Pharma Major Business
7.10.3 Luye Pharma Liposomal-based Drug Product and Services
7.10.4 Luye Pharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Luye Pharma Recent Developments/Updates
7.10.6 Luye Pharma Competitive Strengths & Weaknesses
7.11 Leadiant Biosciences
7.11.1 Leadiant Biosciences Details
7.11.2 Leadiant Biosciences Major Business
7.11.3 Leadiant Biosciences Liposomal-based Drug Product and Services
7.11.4 Leadiant Biosciences Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Leadiant Biosciences Recent Developments/Updates
7.11.6 Leadiant Biosciences Competitive Strengths & Weaknesses
7.12 Ipsen
7.12.1 Ipsen Details
7.12.2 Ipsen Major Business
7.12.3 Ipsen Liposomal-based Drug Product and Services
7.12.4 Ipsen Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Ipsen Recent Developments/Updates
7.12.6 Ipsen Competitive Strengths & Weaknesses
7.13 Sayre Therapeutics
7.13.1 Sayre Therapeutics Details
7.13.2 Sayre Therapeutics Major Business
7.13.3 Sayre Therapeutics Liposomal-based Drug Product and Services
7.13.4 Sayre Therapeutics Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Sayre Therapeutics Recent Developments/Updates
7.13.6 Sayre Therapeutics Competitive Strengths & Weaknesses
7.14 Jazz
7.14.1 Jazz Details
7.14.2 Jazz Major Business
7.14.3 Jazz Liposomal-based Drug Product and Services
7.14.4 Jazz Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Jazz Recent Developments/Updates
7.14.6 Jazz Competitive Strengths & Weaknesses
7.15 Alnylam
7.15.1 Alnylam Details
7.15.2 Alnylam Major Business
7.15.3 Alnylam Liposomal-based Drug Product and Services
7.15.4 Alnylam Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Alnylam Recent Developments/Updates
7.15.6 Alnylam Competitive Strengths & Weaknesses
7.16 Bausch Health
7.16.1 Bausch Health Details
7.16.2 Bausch Health Major Business
7.16.3 Bausch Health Liposomal-based Drug Product and Services
7.16.4 Bausch Health Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Bausch Health Recent Developments/Updates
7.16.6 Bausch Health Competitive Strengths & Weaknesses
7.17 Acrotech Biopharma
7.17.1 Acrotech Biopharma Details
7.17.2 Acrotech Biopharma Major Business
7.17.3 Acrotech Biopharma Liposomal-based Drug Product and Services
7.17.4 Acrotech Biopharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Acrotech Biopharma Recent Developments/Updates
7.17.6 Acrotech Biopharma Competitive Strengths & Weaknesses
7.18 Takeda
7.18.1 Takeda Details
7.18.2 Takeda Major Business
7.18.3 Takeda Liposomal-based Drug Product and Services
7.18.4 Takeda Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.18.5 Takeda Recent Developments/Updates
7.18.6 Takeda Competitive Strengths & Weaknesses
7.19 Chiesi Farmaceutici
7.19.1 Chiesi Farmaceutici Details
7.19.2 Chiesi Farmaceutici Major Business
7.19.3 Chiesi Farmaceutici Liposomal-based Drug Product and Services
7.19.4 Chiesi Farmaceutici Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.19.5 Chiesi Farmaceutici Recent Developments/Updates
7.19.6 Chiesi Farmaceutici Competitive Strengths & Weaknesses
7.20 Gilead Sciences
7.20.1 Gilead Sciences Details
7.20.2 Gilead Sciences Major Business
7.20.3 Gilead Sciences Liposomal-based Drug Product and Services
7.20.4 Gilead Sciences Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.20.5 Gilead Sciences Recent Developments/Updates
7.20.6 Gilead Sciences Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Liposomal-based Drug Industry Chain
8.2 Liposomal-based Drug Upstream Analysis
8.3 Liposomal-based Drug Midstream Analysis
8.4 Liposomal-based Drug Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Liposomal-based Drug Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Liposomal-based Drug Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Liposomal-based Drug Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Liposomal-based Drug Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Liposomal-based Drug Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Liposomal-based Drug Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Liposomal-based Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Liposomal-based Drug Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Liposomal-based Drug Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Liposomal-based Drug Players in 2022
Table 12. World Liposomal-based Drug Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Liposomal-based Drug Company Evaluation Quadrant
Table 14. Head Office of Key Liposomal-based Drug Player
Table 15. Liposomal-based Drug Market: Company Product Type Footprint
Table 16. Liposomal-based Drug Market: Company Product Application Footprint
Table 17. Liposomal-based Drug Mergers & Acquisitions Activity
Table 18. United States VS China Liposomal-based Drug Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Liposomal-based Drug Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Liposomal-based Drug Companies, Headquarters (States, Country)
Table 21. United States Based Companies Liposomal-based Drug Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Liposomal-based Drug Revenue Market Share (2018-2023)
Table 23. China Based Liposomal-based Drug Companies, Headquarters (Province, Country)
Table 24. China Based Companies Liposomal-based Drug Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Liposomal-based Drug Revenue Market Share (2018-2023)
Table 26. Rest of World Based Liposomal-based Drug Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Liposomal-based Drug Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Liposomal-based Drug Revenue Market Share (2018-2023)
Table 29. World Liposomal-based Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Liposomal-based Drug Market Size by Type (2018-2023) & (USD Million)
Table 31. World Liposomal-based Drug Market Size by Type (2024-2029) & (USD Million)
Table 32. World Liposomal-based Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Liposomal-based Drug Market Size by Application (2018-2023) & (USD Million)
Table 34. World Liposomal-based Drug Market Size by Application (2024-2029) & (USD Million)
Table 35. Johnson & Johnson Basic Information, Area Served and Competitors
Table 36. Johnson & Johnson Major Business
Table 37. Johnson & Johnson Liposomal-based Drug Product and Services
Table 38. Johnson & Johnson Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Johnson & Johnson Recent Developments/Updates
Table 40. Johnson & Johnson Competitive Strengths & Weaknesses
Table 41. Sun Pharmaceutical Basic Information, Area Served and Competitors
Table 42. Sun Pharmaceutical Major Business
Table 43. Sun Pharmaceutical Liposomal-based Drug Product and Services
Table 44. Sun Pharmaceutical Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Sun Pharmaceutical Recent Developments/Updates
Table 46. Sun Pharmaceutical Competitive Strengths & Weaknesses
Table 47. CSPC Basic Information, Area Served and Competitors
Table 48. CSPC Major Business
Table 49. CSPC Liposomal-based Drug Product and Services
Table 50. CSPC Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. CSPC Recent Developments/Updates
Table 52. CSPC Competitive Strengths & Weaknesses
Table 53. Kinyond Basic Information, Area Served and Competitors
Table 54. Kinyond Major Business
Table 55. Kinyond Liposomal-based Drug Product and Services
Table 56. Kinyond Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Kinyond Recent Developments/Updates
Table 58. Kinyond Competitive Strengths & Weaknesses
Table 59. Teva Basic Information, Area Served and Competitors
Table 60. Teva Major Business
Table 61. Teva Liposomal-based Drug Product and Services
Table 62. Teva Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Teva Recent Developments/Updates
Table 64. Teva Competitive Strengths & Weaknesses
Table 65. Fudan-Zhangjiang Basic Information, Area Served and Competitors
Table 66. Fudan-Zhangjiang Major Business
Table 67. Fudan-Zhangjiang Liposomal-based Drug Product and Services
Table 68. Fudan-Zhangjiang Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Fudan-Zhangjiang Recent Developments/Updates
Table 70. Fudan-Zhangjiang Competitive Strengths & Weaknesses
Table 71. Zydus Cadila Basic Information, Area Served and Competitors
Table 72. Zydus Cadila Major Business
Table 73. Zydus Cadila Liposomal-based Drug Product and Services
Table 74. Zydus Cadila Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Zydus Cadila Recent Developments/Updates
Table 76. Zydus Cadila Competitive Strengths & Weaknesses
Table 77. TTY Biopharma Basic Information, Area Served and Competitors
Table 78. TTY Biopharma Major Business
Table 79. TTY Biopharma Liposomal-based Drug Product and Services
Table 80. TTY Biopharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. TTY Biopharma Recent Developments/Updates
Table 82. TTY Biopharma Competitive Strengths & Weaknesses
Table 83. Pacira Basic Information, Area Served and Competitors
Table 84. Pacira Major Business
Table 85. Pacira Liposomal-based Drug Product and Services
Table 86. Pacira Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Pacira Recent Developments/Updates
Table 88. Pacira Competitive Strengths & Weaknesses
Table 89. Luye Pharma Basic Information, Area Served and Competitors
Table 90. Luye Pharma Major Business
Table 91. Luye Pharma Liposomal-based Drug Product and Services
Table 92. Luye Pharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Luye Pharma Recent Developments/Updates
Table 94. Luye Pharma Competitive Strengths & Weaknesses
Table 95. Leadiant Biosciences Basic Information, Area Served and Competitors
Table 96. Leadiant Biosciences Major Business
Table 97. Leadiant Biosciences Liposomal-based Drug Product and Services
Table 98. Leadiant Biosciences Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Leadiant Biosciences Recent Developments/Updates
Table 100. Leadiant Biosciences Competitive Strengths & Weaknesses
Table 101. Ipsen Basic Information, Area Served and Competitors
Table 102. Ipsen Major Business
Table 103. Ipsen Liposomal-based Drug Product and Services
Table 104. Ipsen Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Ipsen Recent Developments/Updates
Table 106. Ipsen Competitive Strengths & Weaknesses
Table 107. Sayre Therapeutics Basic Information, Area Served and Competitors
Table 108. Sayre Therapeutics Major Business
Table 109. Sayre Therapeutics Liposomal-based Drug Product and Services
Table 110. Sayre Therapeutics Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Sayre Therapeutics Recent Developments/Updates
Table 112. Sayre Therapeutics Competitive Strengths & Weaknesses
Table 113. Jazz Basic Information, Area Served and Competitors
Table 114. Jazz Major Business
Table 115. Jazz Liposomal-based Drug Product and Services
Table 116. Jazz Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Jazz Recent Developments/Updates
Table 118. Jazz Competitive Strengths & Weaknesses
Table 119. Alnylam Basic Information, Area Served and Competitors
Table 120. Alnylam Major Business
Table 121. Alnylam Liposomal-based Drug Product and Services
Table 122. Alnylam Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Alnylam Recent Developments/Updates
Table 124. Alnylam Competitive Strengths & Weaknesses
Table 125. Bausch Health Basic Information, Area Served and Competitors
Table 126. Bausch Health Major Business
Table 127. Bausch Health Liposomal-based Drug Product and Services
Table 128. Bausch Health Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Bausch Health Recent Developments/Updates
Table 130. Bausch Health Competitive Strengths & Weaknesses
Table 131. Acrotech Biopharma Basic Information, Area Served and Competitors
Table 132. Acrotech Biopharma Major Business
Table 133. Acrotech Biopharma Liposomal-based Drug Product and Services
Table 134. Acrotech Biopharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. Acrotech Biopharma Recent Developments/Updates
Table 136. Acrotech Biopharma Competitive Strengths & Weaknesses
Table 137. Takeda Basic Information, Area Served and Competitors
Table 138. Takeda Major Business
Table 139. Takeda Liposomal-based Drug Product and Services
Table 140. Takeda Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 141. Takeda Recent Developments/Updates
Table 142. Takeda Competitive Strengths & Weaknesses
Table 143. Chiesi Farmaceutici Basic Information, Area Served and Competitors
Table 144. Chiesi Farmaceutici Major Business
Table 145. Chiesi Farmaceutici Liposomal-based Drug Product and Services
Table 146. Chiesi Farmaceutici Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 147. Chiesi Farmaceutici Recent Developments/Updates
Table 148. Gilead Sciences Basic Information, Area Served and Competitors
Table 149. Gilead Sciences Major Business
Table 150. Gilead Sciences Liposomal-based Drug Product and Services
Table 151. Gilead Sciences Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 152. Global Key Players of Liposomal-based Drug Upstream (Raw Materials)
Table 153. Liposomal-based Drug Typical Customers
Table 1. World Liposomal-based Drug Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Liposomal-based Drug Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Liposomal-based Drug Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Liposomal-based Drug Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Liposomal-based Drug Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Liposomal-based Drug Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Liposomal-based Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Liposomal-based Drug Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Liposomal-based Drug Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Liposomal-based Drug Players in 2022
Table 12. World Liposomal-based Drug Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Liposomal-based Drug Company Evaluation Quadrant
Table 14. Head Office of Key Liposomal-based Drug Player
Table 15. Liposomal-based Drug Market: Company Product Type Footprint
Table 16. Liposomal-based Drug Market: Company Product Application Footprint
Table 17. Liposomal-based Drug Mergers & Acquisitions Activity
Table 18. United States VS China Liposomal-based Drug Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Liposomal-based Drug Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Liposomal-based Drug Companies, Headquarters (States, Country)
Table 21. United States Based Companies Liposomal-based Drug Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Liposomal-based Drug Revenue Market Share (2018-2023)
Table 23. China Based Liposomal-based Drug Companies, Headquarters (Province, Country)
Table 24. China Based Companies Liposomal-based Drug Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Liposomal-based Drug Revenue Market Share (2018-2023)
Table 26. Rest of World Based Liposomal-based Drug Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Liposomal-based Drug Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Liposomal-based Drug Revenue Market Share (2018-2023)
Table 29. World Liposomal-based Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Liposomal-based Drug Market Size by Type (2018-2023) & (USD Million)
Table 31. World Liposomal-based Drug Market Size by Type (2024-2029) & (USD Million)
Table 32. World Liposomal-based Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Liposomal-based Drug Market Size by Application (2018-2023) & (USD Million)
Table 34. World Liposomal-based Drug Market Size by Application (2024-2029) & (USD Million)
Table 35. Johnson & Johnson Basic Information, Area Served and Competitors
Table 36. Johnson & Johnson Major Business
Table 37. Johnson & Johnson Liposomal-based Drug Product and Services
Table 38. Johnson & Johnson Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Johnson & Johnson Recent Developments/Updates
Table 40. Johnson & Johnson Competitive Strengths & Weaknesses
Table 41. Sun Pharmaceutical Basic Information, Area Served and Competitors
Table 42. Sun Pharmaceutical Major Business
Table 43. Sun Pharmaceutical Liposomal-based Drug Product and Services
Table 44. Sun Pharmaceutical Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Sun Pharmaceutical Recent Developments/Updates
Table 46. Sun Pharmaceutical Competitive Strengths & Weaknesses
Table 47. CSPC Basic Information, Area Served and Competitors
Table 48. CSPC Major Business
Table 49. CSPC Liposomal-based Drug Product and Services
Table 50. CSPC Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. CSPC Recent Developments/Updates
Table 52. CSPC Competitive Strengths & Weaknesses
Table 53. Kinyond Basic Information, Area Served and Competitors
Table 54. Kinyond Major Business
Table 55. Kinyond Liposomal-based Drug Product and Services
Table 56. Kinyond Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Kinyond Recent Developments/Updates
Table 58. Kinyond Competitive Strengths & Weaknesses
Table 59. Teva Basic Information, Area Served and Competitors
Table 60. Teva Major Business
Table 61. Teva Liposomal-based Drug Product and Services
Table 62. Teva Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Teva Recent Developments/Updates
Table 64. Teva Competitive Strengths & Weaknesses
Table 65. Fudan-Zhangjiang Basic Information, Area Served and Competitors
Table 66. Fudan-Zhangjiang Major Business
Table 67. Fudan-Zhangjiang Liposomal-based Drug Product and Services
Table 68. Fudan-Zhangjiang Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Fudan-Zhangjiang Recent Developments/Updates
Table 70. Fudan-Zhangjiang Competitive Strengths & Weaknesses
Table 71. Zydus Cadila Basic Information, Area Served and Competitors
Table 72. Zydus Cadila Major Business
Table 73. Zydus Cadila Liposomal-based Drug Product and Services
Table 74. Zydus Cadila Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Zydus Cadila Recent Developments/Updates
Table 76. Zydus Cadila Competitive Strengths & Weaknesses
Table 77. TTY Biopharma Basic Information, Area Served and Competitors
Table 78. TTY Biopharma Major Business
Table 79. TTY Biopharma Liposomal-based Drug Product and Services
Table 80. TTY Biopharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. TTY Biopharma Recent Developments/Updates
Table 82. TTY Biopharma Competitive Strengths & Weaknesses
Table 83. Pacira Basic Information, Area Served and Competitors
Table 84. Pacira Major Business
Table 85. Pacira Liposomal-based Drug Product and Services
Table 86. Pacira Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Pacira Recent Developments/Updates
Table 88. Pacira Competitive Strengths & Weaknesses
Table 89. Luye Pharma Basic Information, Area Served and Competitors
Table 90. Luye Pharma Major Business
Table 91. Luye Pharma Liposomal-based Drug Product and Services
Table 92. Luye Pharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Luye Pharma Recent Developments/Updates
Table 94. Luye Pharma Competitive Strengths & Weaknesses
Table 95. Leadiant Biosciences Basic Information, Area Served and Competitors
Table 96. Leadiant Biosciences Major Business
Table 97. Leadiant Biosciences Liposomal-based Drug Product and Services
Table 98. Leadiant Biosciences Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Leadiant Biosciences Recent Developments/Updates
Table 100. Leadiant Biosciences Competitive Strengths & Weaknesses
Table 101. Ipsen Basic Information, Area Served and Competitors
Table 102. Ipsen Major Business
Table 103. Ipsen Liposomal-based Drug Product and Services
Table 104. Ipsen Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Ipsen Recent Developments/Updates
Table 106. Ipsen Competitive Strengths & Weaknesses
Table 107. Sayre Therapeutics Basic Information, Area Served and Competitors
Table 108. Sayre Therapeutics Major Business
Table 109. Sayre Therapeutics Liposomal-based Drug Product and Services
Table 110. Sayre Therapeutics Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Sayre Therapeutics Recent Developments/Updates
Table 112. Sayre Therapeutics Competitive Strengths & Weaknesses
Table 113. Jazz Basic Information, Area Served and Competitors
Table 114. Jazz Major Business
Table 115. Jazz Liposomal-based Drug Product and Services
Table 116. Jazz Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Jazz Recent Developments/Updates
Table 118. Jazz Competitive Strengths & Weaknesses
Table 119. Alnylam Basic Information, Area Served and Competitors
Table 120. Alnylam Major Business
Table 121. Alnylam Liposomal-based Drug Product and Services
Table 122. Alnylam Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Alnylam Recent Developments/Updates
Table 124. Alnylam Competitive Strengths & Weaknesses
Table 125. Bausch Health Basic Information, Area Served and Competitors
Table 126. Bausch Health Major Business
Table 127. Bausch Health Liposomal-based Drug Product and Services
Table 128. Bausch Health Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Bausch Health Recent Developments/Updates
Table 130. Bausch Health Competitive Strengths & Weaknesses
Table 131. Acrotech Biopharma Basic Information, Area Served and Competitors
Table 132. Acrotech Biopharma Major Business
Table 133. Acrotech Biopharma Liposomal-based Drug Product and Services
Table 134. Acrotech Biopharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. Acrotech Biopharma Recent Developments/Updates
Table 136. Acrotech Biopharma Competitive Strengths & Weaknesses
Table 137. Takeda Basic Information, Area Served and Competitors
Table 138. Takeda Major Business
Table 139. Takeda Liposomal-based Drug Product and Services
Table 140. Takeda Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 141. Takeda Recent Developments/Updates
Table 142. Takeda Competitive Strengths & Weaknesses
Table 143. Chiesi Farmaceutici Basic Information, Area Served and Competitors
Table 144. Chiesi Farmaceutici Major Business
Table 145. Chiesi Farmaceutici Liposomal-based Drug Product and Services
Table 146. Chiesi Farmaceutici Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 147. Chiesi Farmaceutici Recent Developments/Updates
Table 148. Gilead Sciences Basic Information, Area Served and Competitors
Table 149. Gilead Sciences Major Business
Table 150. Gilead Sciences Liposomal-based Drug Product and Services
Table 151. Gilead Sciences Liposomal-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 152. Global Key Players of Liposomal-based Drug Upstream (Raw Materials)
Table 153. Liposomal-based Drug Typical Customers
LIST OF FIGURES
Figure 1. Liposomal-based Drug Picture
Figure 2. World Liposomal-based Drug Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Liposomal-based Drug Total Market Size (2018-2029) & (USD Million)
Figure 4. World Liposomal-based Drug Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Liposomal-based Drug Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Liposomal-based Drug Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Liposomal-based Drug Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Liposomal-based Drug Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Liposomal-based Drug Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Liposomal-based Drug Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Liposomal-based Drug Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Liposomal-based Drug Revenue (2018-2029) & (USD Million)
Figure 13. Liposomal-based Drug Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Liposomal-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 16. World Liposomal-based Drug Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Liposomal-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 18. China Liposomal-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Liposomal-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Liposomal-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Liposomal-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Liposomal-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 23. India Liposomal-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Liposomal-based Drug by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Liposomal-based Drug Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Liposomal-based Drug Markets in 2022
Figure 27. United States VS China: Liposomal-based Drug Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Liposomal-based Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Liposomal-based Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Liposomal-based Drug Market Size Market Share by Type in 2022
Figure 31. Liposomes Drugs
Figure 32. Lipid Nanoparticle Drugs
Figure 33. World Liposomal-based Drug Market Size Market Share by Type (2018-2029)
Figure 34. World Liposomal-based Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 35. World Liposomal-based Drug Market Size Market Share by Application in 2022
Figure 36. Hospital
Figure 37. Retail Pharmacy
Figure 38. Other
Figure 39. Liposomal-based Drug Industrial Chain
Figure 40. Methodology
Figure 41. Research Process and Data Source
Figure 1. Liposomal-based Drug Picture
Figure 2. World Liposomal-based Drug Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Liposomal-based Drug Total Market Size (2018-2029) & (USD Million)
Figure 4. World Liposomal-based Drug Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Liposomal-based Drug Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Liposomal-based Drug Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Liposomal-based Drug Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Liposomal-based Drug Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Liposomal-based Drug Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Liposomal-based Drug Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Liposomal-based Drug Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Liposomal-based Drug Revenue (2018-2029) & (USD Million)
Figure 13. Liposomal-based Drug Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Liposomal-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 16. World Liposomal-based Drug Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Liposomal-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 18. China Liposomal-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Liposomal-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Liposomal-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Liposomal-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Liposomal-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 23. India Liposomal-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Liposomal-based Drug by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Liposomal-based Drug Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Liposomal-based Drug Markets in 2022
Figure 27. United States VS China: Liposomal-based Drug Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Liposomal-based Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Liposomal-based Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Liposomal-based Drug Market Size Market Share by Type in 2022
Figure 31. Liposomes Drugs
Figure 32. Lipid Nanoparticle Drugs
Figure 33. World Liposomal-based Drug Market Size Market Share by Type (2018-2029)
Figure 34. World Liposomal-based Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 35. World Liposomal-based Drug Market Size Market Share by Application in 2022
Figure 36. Hospital
Figure 37. Retail Pharmacy
Figure 38. Other
Figure 39. Liposomal-based Drug Industrial Chain
Figure 40. Methodology
Figure 41. Research Process and Data Source